Axinn Advised Thermo Fisher on $12.5B Acquisition of QIAGEN
March 3, 2020
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed $12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ACI 22nd Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
Informa 35th Annual Advanced EU London Conference
Speaking Engagement
Antitrust
Antitrust Fault Lines: Will Licensing Negotiation Groups Reshape SEP Licensing?
Byline Articles
Antitrust
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
Kenina Lee Selected as a Member of Law360’s 2026 Competition Editorial Advisory Board
Awards & Recognitions
Antitrust
Axinn Associates at the Antitrust Spring Meeting: You Get a Deal, You Get a Deal—A Deal in Every Environment
Axinn Viewpoints
Antitrust
Axinn Associates at the Spring Meeting: Trends in Federal Antitrust Enforcement and Policy
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Cartel Enforcement Trends and Developments
Axinn Viewpoints
Antitrust
Axinn Associates at the Antitrust Spring Meeting: Tech-Related Enforcement
Axinn Viewpoints
Antitrust
Leadership Across the Generations: A Conversation Between Mentor and Mentee
Byline Articles
Antitrust
